Tue, Sep 30, 2014, 11:18 AM EDT - U.S. Markets close in 4 hrs 42 mins

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • jairy47 jairy47 May 17, 2013 8:48 AM Flag

    CHMP Report On MAA Withdrawal Of Raxone

    This gives some insight into the process and perhaps Arena's decision to withdraw the MAA for Lorcaserin. It appears that Raxone received a negative opinion from CHMP and applied for reconsideration. From the withdrawal letter it seems that Santhera wanted to submit new data and analysis but was told that they couldn't so they withdrew the MAA. I'm thinking Arena withdrew before receiving a negative opinion to keep open the possibility of submitting new data. This info is included in the April CHMP monthly report. The reason for the negative opinion was that the benefit did not outweigh the risk.....something CHMP asked Arena to address.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Reason for the withdrawl? Merger. Acquisition. Reapply under big pharma with heavy hands.

    • If what some are saying is true, Arena will re-apply Locacsrien / Belviq as a diabetes drug first weight loss second making the benefits outweighing the risk, I did hear Robert say during the presentation that Arena is actively exploring other opportunities for Lorcaserin / Belviq.

      Sentiment: Strong Buy

    • Wait and see.

      Below are few examples of withdrawals:

      OraNera: "Additional new data and analysis would be required in order to obtain a favorable opinion, which however the company is not able to generate within the timeframe allowed in the centralized procedure"

      Ruvise: "This decision was taken since additional data are required in order to address CHMP questions relating to the benefit/risk assessment of imatinib in P AH patients. These data will not be available within the timeframe allowed in the Centralized Procedure."

      Combimarv: "The decision to withdraw is in order to have sufficient time to repeat and submit bioequivalence T1D PK/PD data on each clamp study in order to comply with planned new insulin guideline, at a validated CRO.

      Sentiment: Strong Buy

    • "The reason for the negative opinion was that the benefit did not outweigh the risk" . . . and that, after all, is at the heart of it . . . and, likely, ARNA's stagnant share price . . .

      • 3 Replies to neo17a
      • ARNA does not need the CHMP we just need June 7th to start sales in the US where all the really fat people are anyway!

        Sentiment: Strong Sell

      • Let's be honest here. There is perceived benefit and perceived risk. If CHMP stumbled the same way that shorts stumble on efficacy (seeing the 4% margin over placebo) then they are blind to the 11% weight loss among responders. That is a significant benefit in terms of real world experience.

        Now, what exactly ARE the risks? Schedule IV classification means abuse potential is present but low. Heart valve damage was finally laid to rest this week with a published study. Rat tumors? I doubt it.

        I like the idea that someone else floated here. Maybe Arena started to feel that the EU is just not clamoring for an obesity drug to start with. They turned Qsymia down and nobody else is in the wings presently (Contrave?). Perhaps Arena feels that the BLOOM and BLOSSOM trials were strong enough to re-submit as a Type II Diabetes drug. Nobody in their right mind could argue that diabetes is not a life threatening disease.

      • You're on the wrong board, so go to VVUS.

 
ARNA
4.250.00(0.00%)11:17 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.